The new P-CAB family of gastroesophageal reflux disease treatment for K-CAB, the 30th new domestic drug, is K-CAB. Since its launch in 2019, it has recorded growth every year, boasting more than 100 billion won in annual sales.
It has been on a roll, recording accumulated sales of 478.8 billion won in the first 10 months of last year.
It's literally a 'blockbuster' product.
It seems that a strong challenge is starting for this K-cap. Several domestic pharmaceutical companies have begun to compete in related markets, including the Patent Tribunal's request to release K-cap patents.
According to the pharmaceutical industry on the 5th, more than 60 domestic pharmaceutical companies, including Tama Pharmaceutical and Samcheondang Pharmaceutical, won some of the K-Cap passive rights confirmation trials filed with the Patent Tribunal.
K-Cap has three major patents.
These include crystalline patents and use patents that expire in 2036, and material patents that expire in 2031.
In the lawsuit, Hae-hae Pharmaceutical and Samcheondang Pharmaceutical won some of the decisive patents that expire in 2036.
In this regard, attention is being paid to what position HK Innoen, who holds the K-cap, will present.
Meanwhile, HK Innoen is jointly selling K-cap with Boryeong this year.
The two companies recently signed a domestic joint sales and marketing contract for representative items K-Cap and Kanab.
Kwak Dal-won, president of HK Innoen, said, "The cooperation between the two companies that created the new blockbuster drug is a new attempt that has been hard to find.“
[WIKI KOREA=Cho Pil Hyun, Staff Reporter]
chop23@wikileaks-kr.org
